ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook
JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.
Zacks·5d ago
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Zacks·25d ago
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
Zacks·3mo ago
What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?
Pharma giant Bristol-Myers Squibb has notably outpaced the broader pharma industry over the past year and analysts remain moderately bullish on the stock’s prospects.